FI3442537T3 - (+)-Atsasetroni käytettäväksi korvaan liittyvien häiriöiden hoitoon - Google Patents

(+)-Atsasetroni käytettäväksi korvaan liittyvien häiriöiden hoitoon Download PDF

Info

Publication number
FI3442537T3
FI3442537T3 FIEP17717441.4T FI17717441T FI3442537T3 FI 3442537 T3 FI3442537 T3 FI 3442537T3 FI 17717441 T FI17717441 T FI 17717441T FI 3442537 T3 FI3442537 T3 FI 3442537T3
Authority
FI
Finland
Prior art keywords
composition
use according
ear
hearing loss
azasetron
Prior art date
Application number
FIEP17717441.4T
Other languages
English (en)
Finnish (fi)
Inventor
Jonas Dyhrfjeld-Johnsen
Original Assignee
Sensorion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sensorion filed Critical Sensorion
Priority claimed from PCT/EP2017/059058 external-priority patent/WO2017178645A1/en
Application granted granted Critical
Publication of FI3442537T3 publication Critical patent/FI3442537T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP17717441.4T 2016-04-14 2017-04-14 (+)-Atsasetroni käytettäväksi korvaan liittyvien häiriöiden hoitoon FI3442537T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322690P 2016-04-14 2016-04-14
EP16180192 2016-07-19
PCT/EP2017/059058 WO2017178645A1 (en) 2016-04-14 2017-04-14 (+)-azasetron for use in the treatment of ear disorders

Publications (1)

Publication Number Publication Date
FI3442537T3 true FI3442537T3 (fi) 2024-04-04

Family

ID=65588799

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP17717441.4T FI3442537T3 (fi) 2016-04-14 2017-04-14 (+)-Atsasetroni käytettäväksi korvaan liittyvien häiriöiden hoitoon

Country Status (18)

Country Link
US (2) US11612605B2 (https=)
EP (1) EP4335508A3 (https=)
JP (1) JP7158723B2 (https=)
CN (1) CN109310698B (https=)
AU (1) AU2023202897B2 (https=)
CL (1) CL2018002930A1 (https=)
DK (1) DK3442537T3 (https=)
ES (1) ES2975016T3 (https=)
FI (1) FI3442537T3 (https=)
HR (1) HRP20240453T1 (https=)
HU (1) HUE066000T2 (https=)
IL (1) IL262305B (https=)
MX (1) MX384045B (https=)
NZ (1) NZ747201A (https=)
PL (1) PL3442537T3 (https=)
RS (1) RS65379B1 (https=)
SI (1) SI3442537T1 (https=)
ZA (1) ZA201806894B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2882602T3 (es) * 2015-05-18 2021-12-02 Sensorion Azasetrón para usar en el tratamiento de la pérdida auditiva

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
CA1304082C (en) 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB0009914D0 (en) 2000-04-20 2000-06-07 Metris Therapeutics Limited Device
GB0104554D0 (en) 2001-02-23 2001-04-11 Glaxo Group Ltd New uses
US20030044356A1 (en) 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
US20030229333A1 (en) * 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
GB0213869D0 (en) 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
NZ541009A (en) 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating nausea, vomiting, retching or any combination thereof
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US20040204466A1 (en) 2003-04-14 2004-10-14 Orchid Chemicals And Pharmaceuticals Ltd. Treatment of bronchial asthma using 5-HT3 receptor antagonists
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US20100016218A1 (en) 2008-07-14 2010-01-21 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
EP2253316B1 (en) * 2009-05-20 2013-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits
CN102458400B (zh) 2009-05-20 2014-10-08 国立健康与医学研究所 用于治疗病灶性前庭功能障碍的血清素5-ht3受体拮抗剂
CN101786963B (zh) 2010-03-03 2013-05-08 山东众诚药业股份有限公司 阿扎司琼中间体的合成方法
JP2015511242A (ja) 2012-02-23 2015-04-16 インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル) 病変性前庭障害の治療に使用するカルシニューリン阻害剤
EP2872128B1 (en) 2012-07-16 2020-02-19 Cornell University Nicotinamide riboside to treat hearing loss
BR112016002205A2 (pt) * 2013-07-31 2017-08-01 Bluepharma Ind Farmaceutica S A filmes orodispersíveis
CN104557906A (zh) 2015-01-21 2015-04-29 扬子江药业集团四川海蓉药业有限公司 一种盐酸阿扎司琼的制备方法
ES2882602T3 (es) * 2015-05-18 2021-12-02 Sensorion Azasetrón para usar en el tratamiento de la pérdida auditiva

Also Published As

Publication number Publication date
DK3442537T3 (da) 2024-03-25
EP4335508A3 (en) 2024-07-10
US20230226071A1 (en) 2023-07-20
NZ747201A (en) 2023-02-24
JP7158723B2 (ja) 2022-10-24
US20190083503A1 (en) 2019-03-21
JP2019513780A (ja) 2019-05-30
EP4335508A2 (en) 2024-03-13
IL262305B (en) 2022-03-01
HUE066000T2 (hu) 2024-06-28
US11612605B2 (en) 2023-03-28
IL262305A (en) 2018-11-29
HRP20240453T1 (hr) 2024-06-21
MX2018012587A (es) 2019-03-07
AU2023202897B2 (en) 2025-01-30
CL2018002930A1 (es) 2019-02-15
ES2975016T3 (es) 2024-07-02
SI3442537T1 (sl) 2024-05-31
CN109310698B (zh) 2021-12-24
MX384045B (es) 2025-03-14
PL3442537T3 (pl) 2024-07-15
ZA201806894B (en) 2023-03-29
RS65379B1 (sr) 2024-04-30
AU2023202897A1 (en) 2023-05-25
CN109310698A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
EP3801524B1 (en) Composition and method of treating cancer associated with egfr mutation
JP5612473B2 (ja) 難聴を処置又は予防するための1−アミノ−アルキルシクロヘキサン誘導体
MA56748B1 (fr) Formes à l'état solide de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tétrahydronaphthalén-2-yl)amino)-n-(1-(2-méthyl-1-(néopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide et utilisations assosiées
JP6675313B2 (ja) 組合せ医薬
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
Lin et al. Pharmacology of balance and dizziness
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
CN107847489A (zh) 用于治疗听力损失的司琼类钙调神经磷酸酶抑制剂
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
WO2018060463A3 (en) Treatment of prostate cancer
RU2016143979A (ru) Схема дозирования модулятора s1p с немедленным высвобождением
JP2022502492A5 (https=)
RU2020122083A (ru) Способ снижения ототоксичности у педиатрических пациентов, получающих химиотерапию препаратами платины
RU2019138166A (ru) Средство для профилактики или лечения атрофии головного мозга
CN110636862A (zh) 用于治疗乳腺癌的组合疗法
JP2019516727A5 (https=)
FI3442537T3 (fi) (+)-Atsasetroni käytettäväksi korvaan liittyvien häiriöiden hoitoon
EA038516B1 (ru) Композиция для лечения заболеваний уха, содержащая (+)-азасетрон
ES3030316T3 (en) 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases
EP2982382A1 (en) Compounds for preventing ototoxicity
CN111787922A (zh) 用于治疗肝细胞癌的组合疗法
KR20160086962A (ko) 삼중 음성 유방 암 치료를 위해 카보플라틴과 병용된 벨리파리브
JP2019513780A5 (https=)
TH1801006398A (th) (+)-อะซาชีตรอนสำหรับการใช้ในการรักษาความผิดปกติของหู
EP3454898A1 (en) Drug combinations for reducing cell viability and/or cell proliferation